

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

- Abdominal surgery, 233
- Accessory muscles of respiration, 58, 282
- ACE inhibitors, 260-261
- Acid-base status, 70, 71, 283
- Acidosis, 43, 46, 71, 255
 - severe, 286t, 287t
- Acute bronchospasm. See *Bronchospasm, acute*.
- Adenosine, 259
- Adenosine monophosphate, cyclic. See *Cyclic AMP*.
- Advair/Advair Diskus, 193-197, 194t. See also *Fluticasone/salmeterol*.
 - 250/50 dosage, 196, 206-207, 292, 293
 - 500/50 dosage, 193-195, 196-197, 206-207, 293
 - approved for airflow obstruction in COPD, 206-207
 - approved in COPD with chronic bronchitis, 196, 207
 - exacerbation reduction with, 91-92, 149, 195, 292-295, 294
 - in TORCH trial, 203-207
- Advair HFA, 194t
- Advanced-care planning, 299-302
- Advanced directives, 286
- Aerobec, 184t
- Aerobec Forte, 184t
- Aerobid, 185t
- Aerosol devices, selecting, 214-218, 216t-217t
- Age
 - cognitive decline in aging, 264
 - COPD mortalities and, 19
 - COPD prevalence and, 19, 21
 - as COPD risk factor, 23, 83
 - FEV₁/FVC ratio and, 62
 - loss of lung function with, 21
 - of onset, COPD vs asthma, 53t
- Air pollution, 23, 45, 52t, 83
 - COPD exacerbations and, 278-279, 278t
- Air trapping, 54, 68
- Air travel, oxygen therapy and, 128
- Airflow limitation, 37-38, 39t, 44-45, 133. See also *FEV₁/FVC ratio*.
 - in asthma vs COPD, 35t
 - chronic, in COPD, 51
 - in COPD definition, 17, 21, 133, 247
 - in COPD diagnosis, 37-38, 39t, 40-41, 51, 52, 58-59, 61-64, 133
 - in COPD, irreversibility of, 119
 - definition of, 18, 37
 - in exacerbations, 275, 280t
 - factors contributing to, 133
 - FEV₁ level in, 51
 - flow-volume loops, 66-68, 67
 - lung histology and, 40-41
 - reversibility of, 64-66
 - bronchodilators and, 38t, 42, 43
 - corticosteroids and, 65-66
 - partial, 38t, 42

Airflow limitation (*continued*)
 smoking and, 44-45, 44
 spirometry as test of, 37, 61-64, 63
 staging of COPD based on spirometry, 39t, 61, 247-248, 249t

Airflow obstruction, 32-34, 33
 amount necessary for COPD diagnosis, 31
 bacterial colonization as factor in, 278, 279
 FEV₁/FVC ratio decrease in, 63
 index (BODE index), 42
 pathophysiology of, 32-34
 reversibility of, 38t, 42, 43, 51, 64-66
 surgical improvement of, 234

Airolin, 142t

Airomir, 142t

Airway(s)
 bacterial colonization of, 278, 279
 hyperreactivity/hyperresponsiveness of, 24, 45
 increased resistance of, 37, 38t, 40-41
 normal, 33
 remodeling of, 24
 smooth-muscle hyperplasia of, 34, 141
 thickening of, 38

Airway inflammation, 34, 35t, 37, 43-44
 in asthma vs COPD, 34, 35t
 cells involved in, 36t
 genetic factors in, 34
 small airways, 32-34, 52, 133

Airway obstruction, 32-34, 33. See also *Airflow limitation*;
Airflow obstruction.
 definition of, 18
 FEV₁ and FEV₁/FVC ratio in, 63, 64

Airway smooth muscle
 bronchodilator impact on, 134, 135, 141
 hyperplasia of, 34, 141
 muscarinic receptor subtypes on, 162-163, 163

Albumin, serum, 277

Albuterol, 66t, 140, 142t-143t, 284
 combined with anticholinergic (ipratropium), 174, 176-177, 194t, 196-197

Albuterol/ipratropium, 174, 176-177, 194t, 196-197

Alkalosis, 258, 260

Allergies, inquiry about, 57

α_1 -Antitrypsin deficiency, 24, 45
 in emphysema, 32
 prevalence rates, 45
 screening/monitoring for, 75

Alpha-1 Association, 303

α 4 β 2 nicotinic acetylcholine receptor partial agonist (varenicline), 103, 107-111

α -Blockers, 261

Alupent, 140, 144t

Alveolar attachments, loss/disruption of, 32, 33, 37, 40-41, 52, 54, 77

American Academy of Allergy, Asthma, and Immunology, 303

American Academy of Family Physicians (AAFP), 303

American Association for Respiratory Care (AARC), 303

American College of Chest Physicians (ACCP), 303
 treatment guidelines, 245, 246t

American Lung Association (ALA), 304

American Thoracic Society (ATS), 17, 304
 ATS/ERS assessment of symptomatic benefit, 250t
 ATS/ERS definition of COPD, 17, 31, 245-247, 258
 ATS/ERS exacerbation classification, 277
 ATS/ERS guidelines, 218, 246t
 ATS/ERS position paper on diagnosis and treatment, 248, 276, 277
 ATS/ERS spirometric classification of COPD severity, 249t
 treatment guidelines, 245, 246t

Amlodipine, 257

Anabolic steroids, 46, 268

Angina, 258
 treatment of, 259-260

Angiography, 237t

Angioplasty, 260

Angiotensin-converting enzyme (ACE) inhibitors, 260-261

Angiotensin II receptor antagonists, 261

Anorexia, 57, 268

Antibiotics
 for exacerbations, 91, 278, 284-285
 prophylactic, 218-219

Anticholinergics, 160-173. See also *Ipratropium*; *Tiotropium*.
 action mechanisms, 134, 135, 160
 agents, 160, 161t
 ipratropium, 160-162, 161t
 oxitropium, 161t
 tiotropium, 161t, 162-172
 cardiovascular risk and, 173
 in combination
 with albuterol, 160, 174, 176-177, 194t
 with β_2 -agonists, 194t, 251, 284
 with methylxanthines, 210
 with salmeterol, 174, 178
 with theophylline, 175
 triple therapy, 252
 dosage, 161t, 172
 effects of, 160
 efficacy
 ipratropium, 160-162
 tiotropium, 162-171
 for exacerbations of COPD, 284
 inhaled vs systemic, 160
 key points, 172
 long-acting, 161t, 162-163, 250
 safety analysis, 171-172, 173
 short-acting, 161t
 side effects, 160, 172

Antidepressants, 263, 267
 cautions for, 152

Anti-inflammatory medications, 90
 corticosteroids, 82, 193-195
 methylxanthines, 207, 251
 phosphodiesterase-4 (PDE₄) inhibitors, 210-214

Antioxidants, 37, 220t, 221

Anti-protease, 24

Antiproteinases, 24, 37

Antitrypsin deficiency, 24, 32, 45, 75

Antitussives, 220t

Anxiety, 256t, 262-264
 management/treatment of, 122, 263-264
 roflumilast and, 214, 292
 sleep disorders associated with, 266, 267

Anxiolytics, 263-264

APACHE III scores, 277

Apnea, obstructive sleep, 73, 266

Arcapta Neohaler (indacaterol), 141, 146t, 153, 158. See also *Indacaterol*.

Arformoterol (Brovana), 146t, 150-152
 cautions for, 152
 dosage, 146t, 152
 FDA approval of, 150-152

Arrhythmias, 207, 258, 278t

Arterial blood gases, 60, 70, 71
 in exacerbations, 282, 283
 preoperative, 233

Arterial puncture, 70

Asmabec, 184t

Asmasal, 142t

Aspirin, 259

Assessment, 54-73. See also *Diagnosis of COPD*.
 of exacerbations, 282-283
 IC/TLC ratio in, 42
 of symptoms, 54-57

Assisted ventilation. See *Oxygen therapy; Ventilation support*.

Asthma
 age of onset, 53t
 airway inflammation in, 34, 35t
 airway remodeling in, 24
 bronchodilator reversibility in, 65
 chronic, COPD and, 24, 34, 247
 corticosteroid/bronchodilator combinations for, 193
 differential diagnosis, 52-53, 53t
 DLCO in, 69
 exacerbations of, 283
 response to therapy, 35t
 short-acting β_2 -agonist use in, 140
 smoking and, 34
 vs COPD, 34, 35t, 52-53, 53t, 56

Atropine, 160

Atrovent, 161t. See also *Ipratropium*.

Auscultation
 of the chest, 56, 59
 of the heart, 257

Azmacort. See *Triamcinolone*.

B lymphocytes, 36t

Bacterial infections, 56, 278, 278t, 279, 284-285, 289
 gram-negative, 284-285
 treating, 284-285

Bacterial pneumonia, immunization for, 90

Bambec (bambuterol), 143t

Bambuterol (Bambec), 143t

BCSS (breathlessness, cough, and sputum scores), 201

Beclazone, 184t

Becloforte, 184t

Beclomet, 184t

Beclomethasone (beclometasone), 66, 184t

Beclovent, 184t

Becodisk, 184t

Becotide, 184t

Benzodiazepine, 263-264

Berodual (fenoterol/ipratropium), 194t

Berotec (fenoterol), 143t

β_2 -Adrenergic agonists. See β_2 -agonists.

β_2 -Adrenergic receptors, 135, 140

β_2 -Agonists, 139-159
 action mechanisms, 134, 135, 139-140
 adverse effects, 141, 159
 cardiovascular, 159
 sleep disorders, 266
 systemic, 159

β -blockers and, 260
 in combination
 with anticholinergics, 174, 175, 178, 251, 284
 with corticosteroids, 187, 193-207, 194t, 251, 265
 with methylxanthines, 210, 251
 triple therapy, 252
 for exacerbations of COPD, 284
 indications for, 140, 141, 159, 250
 key points, 159
 long-acting (LABA), 90, 141, 146t, 158-159, 250
 in combination with corticosteroids, 193-207, 265
 dosage, 141, 146t, 147, 149-150, 152, 153, 158-159
 efficacy, 141-158
 formoterol, 149-153
 formoterol fumarate inhalation solution (FFIS), 152-153
 indications for, 141, 159
 salmeterol, 141-149
 side effects of, 141, 159
 ultra-long-acting (indacaterol), 153-159

nonbronchodilator effects of, 140

onset and duration of action
 long-acting, 141-147, 149, 153
 short-acting, 140, 158
 steady-state bronchodilation, 141

safety and tolerability, 159

short-acting, 90, 140-141, 142t-145t, 159

agents and formulations, 140, 142t-145t
 dosage, 140, 142t-145t, 158
 effectiveness in COPD, 140-141
 indications for, 140, 159
 loss of effectiveness in asthma, 140
 "rescue" use of, 140, 158
 side effects, 141, 159, 266
 use in asthma, 140

β -Blockers
 for angina, 259
 cardioselective, 260
 cautions for COPD patients, 260
 combined with β -blockers, 261
 for right-heart failure, 258

Bicarbonate, 70, 71

Bioelectric impedance, 124

Bisphosphonate therapy, 263t
 Bitolterol (tornalate), 140, 145t
 Blood gases. See *Arterial blood gases*.
 Blood viscosity, 255, 257, 258-259, 260
 reducing, 259
 BMI. See *Body mass index*.
 BODE Index, 42
 Body mass index (BMI), 46, 124, 248
 definition of, 124
 mortality, impact on, 122-123, 123, 277
 weight categories defined by, 124
 Body plethysmograph, 68
 BOLD (Burden of Lung Disease) study, 21
 Bone mineral loss, 57
 corticosteroids and, 183, 192
 Borg Scale, Modified, 55, 55t
 Bosentan, 257
 Boyle's law, 68
 Breath sounds/pattern, 58-59
 Breathaire, 145t
 Breathing, work of. See *Work of breathing*.
 Breathlessness, cough, and sputum scores (BCSS), 201
 Breathlessness. See *Dyspnea*.
 Brethine, 140, 145t
 Bricanyl, 140, 145t
 Bronchial hyperresponsiveness, 45
 Bronchiectasis, 53, 56
 Bronchioles (in emphysema), 32, 52
 Bronchiolitis, 32-34
 Bronchitis
 acute, 52t
 chronic. See *Chronic bronchitis*.
 Bronchodilators, 137-178, 250-251. See also *specific bronchodilator classes*.
 action mechanisms, 134, 135, 137
 aggressive/first-line therapy with, 139, 222-223, 250-251
 assessing responsiveness, 139, 250t
 bronchodilator combinations, 174-178, 196-197, 251
 key points, 178
 lung function with, 173-178, 176-177, 178, 196-197
 bronchodilator/corticosteroid combinations, 193-207, 194t
 choice of, 250-251
 classes of, 137
 anticholinergics, 160-173
 β_2 -adrenergic agonists, 139-159
 methylxanthines, 207-210
 clinical effects, 137-139, 138
 continuous therapy with, 140
 dosage. See *specific bronchodilators*.
 guidelines, 246t, 250-251
 indications for, 137, 222-223, 246t, 250-251
 exacerbation prevention, 91-92
 exacerbations, 283-284
 key points, 159, 172, 178
 long-acting, 141, 146t, 158-159, 161t, 162-172, 250
 lung function improvement with, 137-139, 138, 141, 166-169, 168, 169, 250
 overview of, 137-139, 222-223
 "rescue" use of, 140, 158

Bronchodilators (*continued*)
 reversibility of airflow obstruction with, 38t, 42, 43, 51
 in asthma, 65
 in COPD diagnosis, 64-66, 66t
 reversibility testing, 64-66
 guidelines for, 66t
 short-acting, 140-141, 142t-145t, 196-197, 222t
 in stepped-care approach to treatment, 222-223, 222t
 Bronchospasm, acute
 adenosine and, 259
 bronchodilators and, 140
 ipratropium not recommended for, 160
 roflumilast not recommended for, 291, 292
 Bronkometer, 143t
 Bronkosol, 143t
 Brovana. See *Arformoterol*.
 Budesonide (Pulmicort), 183-186, 185t, 187, 189
 EUROSOP trial, 183
 Budesonide/formoterol (Symbicort), 194t, 197-202, 198, 252
 adverse events, 201
 efficacy of metered inhaler (Symbicort), 198-199, 200
 end-point effects of, 199, 202
 long-term efficacy and tolerability, 200-201
 in SHINE and SUN trials, 201-202
 tolerability of, 199-201
 Bullae, 75, 77, 79, 234
 Bullectomy, 234-235, 236t-237t
 Bullous disease, 68
 Bupropion, for smoking cessation, 103, 104-107, 106t
 precautions for, 107
 vs varenicline, 107-109, 108
 Burden of disease, 25-26, 26, 28
 Burden of Lung Disease (BOLD) study, 21
 costs, economic and societal, 25-26, 26, 28
 underestimation of, 18
 Buventol, 142t
 Bypass surgery, 260

 C-reactive protein, 259
 Cachexia, 46, 123-124
 Calcium antagonists, 261
 Calcium channel blockers, 257, 260
 Calcium supplements, 263t
 Cancer, 264-265
 Candidiasis, oropharyngeal, 196
 Carbon dioxide production, systemic, 281
 Carbon dioxide retention, 42
 Carbon monoxide diffusion, 69
 Cardiac stress testing, 259
 Cardiology, referrals for, 92, 93t
 Cardiovascular disorders, 60, 255-261, 256t
 exacerbations of COPD and, 282
 other, 258-260
 pulmonary hypertension, 255-257
 right-heart failure (cor pulmonale), 257-258
 systemic hypertension, 260-261

- Cardiovascular side effects
 - of β_2 -agonists, 156, 159
 - of inhaled anticholinergics, 173
- Cardiovascular signs of COPD, 59-60
- Cardiovascular surgery, 233
- Catabolic state, chronic, 46, 47t, 268
- Cataracts, systemic corticosteroids and, 182
- Causes of COPD. See *Risk factors for COPD*.
- Centriacinar (centrilobular) emphysema, 32
- Chantix. See *Varenicline*.
- Chemokines, 210
- Chemotherapy, 265
- Chest
 - pain and tightness in, 56-57
 - percussion and auscultation, 59
 - radiography, 75-80
- Childhood, respiratory disease/infection in, 23, 45, 53t, 57
- Choledyl, 208t
- Chronic bronchitis, 31-32, 33
 - agents approved for
 - Advair Diskus, 196, 207
 - arformoterol, 152
 - corticosteroid/bronchodilator combinations, 196
 - in COPD definition, 17
 - in COPD diagnosis, 51, 52t
 - in COPD pathology, 31-32
 - cost of, 26
 - cough in, 51, 56
 - histopathology, 40-41
 - inclusion in COPD definition, 17
 - mucus secretion in, 32
 - pathologic changes in, 32, 33, 40-41
 - sputum production in, 31-32, 56
 - vs emphysema, 32, 33, 40-41
- Chronic nonspecific lung disease, 45
- Chronic Respiratory Disease Index Questionnaire (CRDQ), 74, 118, 147
- Cigarette smoke. See *Smoking*.
- Cimetidine, 214
- Clinical assessment, 54-73. See also *Diagnosis*.
- Clinical trials. See also *specific agents and therapies*.
 - EUROSOP (inhaled budesonide), 183
 - INSPIRE, 290, 293-295
 - ISOLDE (inhaled fluticasone), 182-183, 186, 187, 188-189
 - Lung Health Study, 95, 96, 183, 187
 - NETT (National Emphysema Treatment Trial), 235, 236, 238-239
 - NOTT (Nocturnal Oxygen Therapy Trial), 126, 126
 - SHINE, 201-202
 - SUN, 201-202
 - TORCH (COPD health), 134, 192, 202-207
 - TRISTAN (inhaled steroids), 183, 195-196, 195
 - UPLIFT (tiotropium), 171, 172, 173, 290
- Cognitive decline, 264
- Cognitive dysfunction, with cardiovascular diseases, 258
- Combination therapy, 251-252. See also *specific agents and classes of agents*.
 - bronchodilator combinations, 174-178, 251
 - corticosteroid/bronchodilator, 193-207, 251, 252
 - for exacerbations, 284
- Combination therapy (*continued*)
 - indications for, 246t
 - with methylxanthines, 210
 - rationale for, 134, 135t, 136, 174
- Combivent, 194t
- Comorbid conditions, 57, 60, 255-274, 256t
 - cancer, 264-265
 - cardiovascular disorders, 60, 255-261
 - exacerbations of COPD and, 278t, 282
 - list of, 256t
 - mental health disorders, 60, 262-264
 - musculoskeletal disorders, 261-262
 - nutritional disorders, 267-269
 - sexual dysfunction, 269
 - sleep disorders, 57, 265-267
- Computed tomography (CT), 78-79, 79, 236t
- Congestive heart failure, 282
- Consultation and referral, 92, 93t
- COPD (chronic obstructive pulmonary disease)
 - definition of, 17, 21, 31, 133, 245-247, 258
 - development and progression of, 43-46
 - economic and social cost of, 25-26, 26, 28
 - as multicomponent, heterogenous disease, 88-89, 90
 - natural history of, 44
 - resources and associations, 303-306
 - stages of, 39t, 62, 249t
 - as systemic disease, 46, 60
 - vs asthma, 35t, 53t
- COPD assessment test (CAT), 74
- COPD Foundation, 304
- COPD-Support, Inc., 304
- Cor pulmonale, 59, 256t, 257-258
- Coronary artery bypass, 260
- Coronary artery disease, 259
- Coronary heart disease, 57, 60
- Corticosteroids, 178-193, 251
 - action mechanisms, 134-137
 - adverse effects, 178-182, 192, 196
 - agents and dosages, 184t-185t
 - combination preparations, 194t
 - anti-inflammatory effects, 82, 193-195
 - clinical studies
 - EUROSOP, 183
 - ISOLDE, 182-183, 186, 187, 188-189
 - in combination
 - with β_2 -agonists, 187, 194t, 223, 251
 - with tiotropium, 290
- COPD exacerbation by, 46
 - corticosteroid/bronchodilator combinations, 193-207, 194t, 251, 252
 - exacerbation prevention with, 91-92, 195-196, 251
 - key points, 207
 - reduced mortality with, 134, 202-207
 - triple therapy, 252
- corticosteroid challenge, 192
- guidelines for, 246t

Corticosteroids (*continued*)

- indications for, 182, 187, 192, 251, 252
 - exacerbation prevention, 284
 - exacerbation reduction, 91, 137, 182-186, 195-196, 289t, 292-295
 - systemic corticosteroids, 182, 252, 284
 - inhaled, 90, 91, 182-193, 184t-185t
 - adverse effects, 192
 - agents and dosage, 184t-185t
 - combination formulations, 183-207, 251
 - disease progression, lack of effect on, 186-190, 188-189
 - effect on exacerbations and health status, 182-186, 183, 289t, 292-295
 - effect on hospitalizations, morbidity, and mortality, 190-192, 190
 - effects on airflow, 187-190
 - efficacy of, 91-92, 182-192
 - indications for, 182, 187, 192, 292
 - initiation of therapy, 136, 192
 - key points, 192-193
 - for prevention of exacerbations, 284
 - reduction of cancer risk and, 265
 - for repeated exacerbations, 91
 - reversibility of airflow limitation with, 65-66
 - in stepped-care approach, 222t, 223
 - systemic, 46, 178-182
 - adverse effects, 46, 178-182, 284
 - beneficial for COPD exacerbations, 182, 252, 284
 - cautions for, 178-182, 223, 261
 - indications for, 182, 252, 284
 - tosterone levels, impact on, 269
- Costs of COPD, 25-26, 26, 28
- Cough, 18, 51, 56
 - ACE inhibitors and, 260-261
 - chronic, 51, 52t, 56
 - in chronic bronchitis, 51, 56
 - in COPD diagnosis, 51, 52t, 56
 - in exacerbations, 277
 - productive, 51, 56
 - sleep disruption due to, 266
 - "smoker's cough," 51, 56
- CRDQ (Chronic Respiratory Disease Index Questionnaire), 74, 118, 147
- Crepitations, 59
- CT. See *Computed tomography*.
- Cyanosis, 58, 282
- Cyclic AMP, 134, 135, 160
- Cyclic GMP, 257
- Cystic fibrosis, 53
- Cytochrome P-450, 263, 264
- Cytochrome P1A2, 214
- Cytochrome P3A4, 214
- Cytokines, 46, 60, 259
 - muscle damage from, 261
 - nutritional disorders and, 268
- Daliresp. See *Roflumilast*.
- Dead space, 72, 280t, 281
- Deconditioning, 46, 57, 116, 261
- Definition of COPD, 17, 31, 133, 245-247
 - ATS/ERS, 17, 31, 245-247, 258

Definition of COPD (*continued*)

- BOLD, 21
 - for diagnosis, 31
 - GOLD, 17, 31, 247
- Dementia, 264
- Depression, 57, 60, 256t, 262-264
 - exacerbations and, 282
 - management/treatment of, 122, 127, 263-264
 - roflumilast and, 214, 292
 - sleep disorders and, 266
- Detection, early. See *Prevention and early detection*.
- Developed countries
 - costs of COPD in, 25, 26, 27
 - mortality from COPD in, 19-20, 19
 - prevalence of COPD in, 17-19, 21, 22
 - smoking and COPD in, 22-23, 22
 - tobacco access in, 18
- Developing countries
 - air pollution and COPD risk in, 23
 - costs of COPD in, 25-26
 - prevalence of COPD in, 18
- Device selection in aerosol therapy, 214-218, 216t-217t
- Diabetes, 57, 60
 - diabetic nephropathy, ACE inhibitors and, 260
 - nicotine-replacement therapy and, 104
 - systemic corticosteroids and, 182
- Diagnosis of COPD, 51-82, 222. See also *Prevention and early detection*.
 - airflow limitation in, 37-38, 39t, 133
 - ATS/ERS position paper on, 248, 276, 277
 - breathlessness as symptom in, 51-52
 - clinical assessment, 54-73
 - arterial blood gases, 60, 70, 71
 - bronchodilator reversibility, 64-66, 66t
 - cardiovascular signs, 59-60
 - chest pain, 56-57
 - chest percussion/auscultation, 59
 - cough and sputum production, 56
 - dyspnea, 54-55, 55t
 - exercise testing, 70-72
 - flow-volume loops, 66-68, 67
 - gas transfer/diffusing capacity, 69
 - IC/TLC ratio, 42
 - peak expiratory flow (PEF), 64
 - physical examination, 58-60
 - pulmonary function tests, 60-70
 - pulmonary vascular pressure, 73
 - radiography, 75-80
 - required tests for all COPD patients, 61-69
 - respiratory muscle function, 72
 - respiratory signs, 58-59
 - right ventricular function, 73
 - sleep studies, 73
 - spirometry, 51, 61-64, 62, 63, 84-85, 133, 246t
 - static lung volumes, 68-69, 68
 - symptoms, 54-57, 55t
 - systemic effects, 60
 - definition of COPD for, 31, 245-247

- Diagnosis of COPD (*continued*)
 differential diagnosis, 51-53, 53t
 early, benefits of, 83, 84
 follow-up/monitoring, 73-80
 histopathology in, 40-41
 history, 54-57
 key indicators, 52t
 multicomponent, heterogenous profile, 88-89, 90
 overview, 51-53, 52t, 84
 by primary care physicians, 15
 screening questionnaire, 86t-87t
 self-report surveys, 18
 staging based on spirometry, 39t, 62
 underdiagnosis, 18, 20
- Diaphragm
 action in breathing, 58
 position of, 58
 radiography of, 75, 76-77
 weight loss/muscle wasting and, 122
- Diarrhea, 212, 214, 292
- Dietary intake. See *Nutrition*.
- Dietician, 92, 119
- Diffusing capacity
 of carbon monoxide (DLCO), 69
 decreased, 38t
- Digitals, 258
- Disease progression, 43-46, 84, 248, 275
 corticosteroid therapy, lack of effect on, 186-190, 188-189
 factors related to, 43-46, 84
 pulmonary rehabilitation impact on, 118-119
 smoking cessation impact on, 133
- Distal acinar (paraseptal) emphysema, 32
- Diuretics
 for cardiovascular disorders, 258, 260
 cautions for, 258
 for osteoporosis, 263t
 sleep disorders and, 267
 theophylline interactions with, 209t
- DLCO (diffusing capacity of carbon monoxide), 69
- Dobutamine infusions, 259
- Doppler echocardiography, 73, 80, 256
- DPIs (dry-powder inhalers), 214, 215, 217t
- Drug interactions, 207, 209t, 214
- Drug-resistant organisms, antibiotic use and, 218
- Dry mouth, 106t, 107, 172
- Dry-powder inhalers (DPIs), 214, 215, 217t. See also *specific medications*.
- DuoNeb, 194t
- Duovent, 194t
- Dutch/Belgian Tiotropium Study Group, 164-166, 165
- "Dutch hypothesis," 45
- Dynamic hyperinflation. See *Hyperinflation*.
- Dyspnea, 39, 52t, 54-55
 in COPD diagnosis, 51, 52t, 54-55, 248
 in COPD exacerbations, 275, 276
 in COPD vs asthma, 53t, 54
 exertional, 52t, 53t, 54, 117
 factors affecting, 54, 166
- Dyspnea (*continued*)
 FEV₁ in, 54
 hyperinflation and, 39, 54
 perception of, 54
 progressive, 52t
 quantification of, 54, 55t
 relieving
 bronchodilators, 137, 139, 160, 166
 corticosteroid/bronchodilator combinations, 196, 199
 exercise training, 116-117
 mechanical ventilation, 286t
 pulmonary rehabilitation, 117, 117t, 120
 scales for, 55, 55t, 248
 self-report surveys, 18
 variability in, 54
- Early detection. See *Prevention and early detection*.
- East London Study, 277
- ECG (electrocardiography), 73
 in pulmonary hypertension, 256, 256t
- Echocardiography, 73, 79-80, 259
- Economic costs of COPD, 25-26, 26, 28
- Edema, 59, 127, 257, 260
- Education, patient. See *Patient education*.
- Elastic recoil, 37-38
 decreased
 in COPD, 37, 38t, 40-41
 hyperinflation and, 38
 static lung volumes and, 66
- Elastolytic proteases, 221
- Electrocardiography (ECG), 72
 in pulmonary hypertension, 256, 256t
 in right-heart failure, 256t, 257
- Elixophyllin, 208t
- Emphysema, 32, 51-52
 α₁-antitrypsin deficiency and, 32
 alveolar attachments, loss/disruption of, 32, 33, 37, 40-41, 52, 54, 77
 arformoterol approved for, 152
 centriacinar vs panacinar, 32
 in COPD definition, 17
 in COPD pathology, 32, 33, 51-52, 90
 cost of, 26
 definition of, 32, 51-52
 diagnostic algorithm, 238-239
 distal acinar (paraseptal), 32
 elastic recoil in, 37-38, 40-41
 histopathology, 40-41
 irregular, 32
 National Emphysema Treatment Trial (NETT), 235, 236, 238-239
 pathologic changes in, 32, 33, 40-41, 42-43
 premature, genetic factors in, 24
 radiographic signs of, 75-77, 76-77, 79
 smoking and, 32
 vs chronic bronchitis, 32, 33, 40-41
- End-of-life care, 91, 92, 93t, 299-302
- End-stage disease, 299-302
- Endothelin-1, 280t

- Endothelin receptor antagonists, 257
- Endotracheal intubation, 285, 286, 300
- Endurance training, 121
- Enoxacin, 214
- Environmental pollution, 83. See also *Air pollution*.
- Eosinophils, 35t, 36t, 193-195
 - in exacerbations, 279, 280t
- Epidemiology of COPD, 14, 17-30
 - COPD definition and, 17, 21
 - mortality rates and, 19-20, 19
 - prevalence rates, 17-21
 - risk factors, 21-25
- Epithelial cells, 36t
- Erectile dysfunction, 269
- Erythrocytosis, 258-259
- Erythromycin, 214
- Estrogen, 24-25
- Ethical issues, in end-stage disease, 299-301
- European Respiratory Society (ERS), 17, 304
 - position statements. See *American Thoracic Society, ATS/ERS subentries*.
- EUROSOP trial, 183
- Exacerbations of COPD, 275-298
 - assessment of, 282-283
 - blood gases in, 70
 - carbon dioxide retention in, 42
 - cardinal features of, 276-277
 - chronic bronchitis and, 279, 291
 - classification of, 276-277
 - clinical findings in, 276
 - comorbidities and, 278t, 282
 - costs of, 25, 28, 275
 - definition of, 276
 - diagnosis of, 276, 282
 - etiology of, 277-279, 278t
 - frequency and duration of, 275, 277
 - reducing, 289t
 - guidelines for treatment, 281t
 - health status, impact on, 91, 252, 275, 277
 - history of, 57
 - hospitalization for, 275, 277, 282, 287
 - discharge criteria, 287, 288t
 - follow-up assessment, 288t
 - indications for, 287, 287t
 - reducing, 290
 - impact of, 275
 - infections and, 277-278, 278t, 279, 284-285, 289
 - inflammatory processes in, 275, 278, 279, 280t
 - management of, 91-92, 281-287, 281t
 - antibiotics, 91, 278, 284-285
 - assessment, 282-283
 - bronchodilator therapy, 91-92, 283-284
 - corticosteroids, 91, 137, 182-186, 223
 - general principles, 252-253, 281-287, 281t
 - history, 282
 - home therapy vs hospital or ICU, 287, 287t, 288t
 - inhaled corticosteroids, 182-183
 - mechanical ventilation, invasive, 286, 286t
- Exacerbations of COPD, management of (*continued*)
 - mechanical ventilation, noninvasive, 285-286
 - mobilization/clearance of secretions, 285
 - oral corticosteroids, 91
 - oxygen therapy, 281, 283
 - prednisone and, 182
 - primary care physicians in, 91
 - systemic corticosteroids, 182, 252
 - mortality from, 275, 277
 - muscle wasting in, 47t
 - pathology of, 279, 280t
 - prevention of, 91-92, 289-295, 289t
 - inhaled steroids, 284, 289t
 - inhaled steroid/anticholinergic combination, 91-92, 251, 289t
 - fluticasone/salmeterol, 292-295, 294
 - pulmonary rehabilitation, 118
 - roflumilast (PDE₄ inhibitor), 289t, 291-292
 - tiotropium, 290, 293-295
 - pulmonary physiology of, 279-281, 280t
 - reducing, 250, 289-295
 - antioxidants, 221
 - bronchodilators, 139, 149, 160, 166, 169, 171, 177, 283-284
 - corticosteroid/bronchodilator combinations, 195-196, 199
 - corticosteroids, 182
 - corticosteroids, inhaled, 289t
 - corticosteroids, systemic, 252
 - FDA-approved agents, 289-295
 - fluticasone/salmeterol combination, 292-295, 294
 - inhaled steroid/anticholinergic, 292-295, 294
 - roflumilast, 289t, 291-292
 - tiotropium, 290, 293-295
 - goal of, 289
 - inhaled corticosteroids, 182
 - pulmonary rehabilitation, 118, 289t
 - respiratory failure in, 277, 281, 283
 - severity classification, 276-277
 - sputum in, 276, 278
 - symptoms, 275, 276, 277
- Exercise, 91, 116-117, 120-121, 223
 - avoidance of, 116
 - BODE index, 42
 - dyspnea in, 39, 52t, 53t, 54
 - exercise testing, 70-72
 - exercise training, 116-117, 118, 120-121, 261
 - for depression management, 263
 - endurance training, 121
 - for osteoporosis management, 263t
 - respiratory muscles, 121
 - strength training, 121
 - treadmill training, 117, 121
 - hyperinflation and, 39
 - oxygen therapy during, 126-127
 - reduction due to COPD, 60, 116
 - 6-minute walk, 42
- Exercise capacity
 - assessing, 70-72
 - deconditioning and, 46, 116, 261

- Exercise capacity (*continued*)
 increasing, 250, 261
 with bronchodilators, 150
 with pulmonary rehabilitation, 117, 117t
 with tiotropium, 168-169, 169, 170
- Exercise tolerance
 improving
 with bronchodilators, 117, 137, 160
 with exercise training, 116-117, 261
 with pulmonary rehabilitation, 117, 117t, 118
 reduction in, 60
 nutrition and, 46
- Expiratory flow rate, 66-68
- Fagerstrom test for nicotine dependence, 104, 105t
- Family/genetic history of COPD, 57, 83. See also *Genetic factors*.
- Family members, in pulmonary rehabilitation support groups, 122
- Fat-free mass (FFM)
 FFM index (FFMI), 124
 measurement of, 124
 reduction in, 46, 47t, 122, 123, 124
 as indication for nutritional intervention, 124
- Fatigue, 57, 275, 282
- Fatty acids, 269
- Fenoterol (Berotec), 143t
- Fenoterol/ipratropium combination agents, 194t
- FEV₁ (forced expiratory volume in 1 second), 61-64
 aging impact on, 62
 calculating and expressing, 61
 chronic airflow limitation, level for, 51
 disease progression and, 84
 impaired, 62-64, 63
 lack of change in COPD, 248-250
 measuring, 61-64
 normal/predicted, 39t, 61-62, 62, 246t
 in COPD stages, 136, 222t
 prediction nomograms, 85, 88, 89
 pharmacotherapy impact on, 135t
 post-bronchodilator, 37, 42, 43, 64-66, 135t
 assessing, 139
 in COPD diagnosis, 64-66
 COPD severity/classification based on, 39t, 247-248, 249t
 pulmonary rehabilitation and, 119, 246t
 as severity stage indicator, 39t, 61-64
 SGRQ and, 74
 smoking and, 44-45, 44
 smoking cessation impact on, 95, 96
 surgery impact on, 234
 vs peak expiratory flow (PEF), 64
- FEV₁/FVC ratio, 61-64
 age and, 62
 airflow limitation defined by, 18, 37
 calculating and expressing, 61
 COPD definition and, 247
 in COPD diagnosis, 31, 61-64, 62, 63
 COPD prevalence based on, 18
 impaired, 62-64, 63
- FEV₁/FVC ratio (*continued*)
 normal/predicted, 37, 39t, 61-62, 62
 in COPD stages, 136, 222t
 prediction nomograms, 85, 88, 89
 post-bronchodilator, 37, 39t, 51
 in smokers, 44
- FFIS (formoterol fumarate inhalation solution), 146t, 152-153
- FFM. See *Fat-free mass*.
- Fibrosis, 32, 38, 291
- Filair, 184t
- Fish oil, 269
- “Five A’s” (smoking cessation strategy), 96, 98t
- “Five R’s” (smoking cessation motivation), 100, 100t
- Flixotide, 185t
- Flovent, 185t
- Flovent Diskus, 185t
- Flow-volume loops, 66-68, 67
- Flu. See *Influenza*.
- Flunisolide, 185t
- Flunitec, 185t
- Fluticasone, 185t
 inhaled
 in ISOLDE trial, 182-183, 186, 187, 188
 in TRISTAN study, 195-196, 195
- Fluticasone propionate, 185t
- Fluticasone/salmeterol (Advair/Advair Diskus), 149, 193-197, 194t, 252
 approved for COPD with chronic bronchitis, 196
 approved for exacerbation reduction, 292-295, 294
 clinical trials
 INSPIRE, 290, 293-295
 TORCH, 134, 192, 202-207
 TRISTAN, 195-196, 195
 in combination with tiotropium, 175-178, 181
 dosage, 194t
 250/50 dosage, 196, 223, 292, 293
 500/50 dosage, 193-195, 196-197, 203, 293
 effects of, 149, 195-196
 anti-inflammatory effects, 193-195c
 exacerbation reduction, 91-92, 149, 195, 292-295, 294
 mortality and survival statistics, 134, 192, 202-207
 in stepped-care approach, 223
 vs tiotropium, 290, 293-295
- Fluvoxamine, 214, 263
- Follow-up and monitoring, 73-80, 85
 after hospital discharge, 287, 288t
 of health status, 74
 other assessments, 74-75
 of smoking cessation, 98t, 99, 287
- Foradil, 141, 146t
- Foradil Aerolizer, 146t
- Forced expiration. See *FEV₁*.
- Forced vital capacity. See *FVC*.
- Formoterol, 146t, 149-153, 198
 in combination with budesonide (Symbicort), 194t, 197-202, 198, 252
 dosage, 146t
 efficacy, 149-150, 151
 enantiomer of (arformoterol), 146t, 150-152

- Formoterol (*continued*)
 formulations, 146t
 formoterol fumarate (Foradil Aerolizer), 141, 146t
 formoterol fumarate inhalation solution (FFIS; Perforomist), 146t, 152-153
 Oxis, 146t
 vs indacaterol, 156-157
 vs ipratropium, 149-150, 151
 Formoterol/budesonide. See *Budesonide/formoterol (Symbicort)*.
 Formoterol fumarate (Foradil Aerolizer), 141, 146t
 Formoterol fumarate inhalation solution (FFIS; Perforomist), 146t, 152-153
 Fractures, vertebral and rib, 262
 Framework Convention on Tobacco Control, 23
 FRC. See *Functional residual capacity*.
 Functional residual capacity (FRC), 68, 139
 FVC (forced vital capacity), 61-64, 62. See also *FEV₁/FVC ratio*.
 definition of, 61
 impaired, 63
 normal, 62
- Gas-exchange abnormalities, 42-43
 in exacerbations, 280-281, 280t, 283
 Gas transfer testing, 69
 Gas trapping, 68, 137. See also *Hyperinflation*.
 Gases
 arterial blood gases, 70, 71
 transfer/diffusing capacity, 69
 Gender
 mortality from COPD and, 19-20, 19
 prevalence of COPD and, 18, 20, 24
 risk of COPD and, 24-25
 smoking and, 22-23, 22
 Genetic factors
 airway inflammation and, 34
 α_1 -antitrypsin deficiency, 24, 45, 75
 candidate gene sites for COPD, 24
 COPD risk and, 23-24, 45
 family history of COPD, 57, 83
 Global Initiative for Chronic Obstructive Lung Disease. See *GOLD*.
 Global Obstructive Lung Disease clinical guidelines, 158
 Glucocorticosteroids, inhaled, 136, 223. See also *Corticosteroids, inhaled*.
 Goblet cells, 32
 GOLD (Global Initiative for Chronic Obstructive Lung Disease), 304
 clinical guidelines, 158, 245, 251-252
 web-based updates, 245
 definition of COPD, 17, 31, 247
 exacerbations of COPD, 277, 278t
 indications for mechanical ventilation, 286, 286t
 pathogenesis of COPD, 37
 spirometric classification of COPD, 39t, 249t
 stages of COPD/stepwise management, 221, 222t, 249t, 251-252
 treatment guidelines, 218, 220t, 245
 Gram-negative pathogens, 284-285
 Growth hormone, human, 268-269
- Haemophilus influenzae (H influenzae)*, 278, 284
 Health care utilization. See also *Hospitalizations*.
 exacerbations and, 252
 pulmonary rehabilitation impact on, 117t
- Health-related quality of life (HRQOL). See *Quality of life*.
 Health status, 74, 91
 exacerbations and, 91, 252, 275, 277
 improving, 250
 with bronchodilators, 137, 139, 165
 with corticosteroid/bronchodilator combinations, 195, 293-295
 with inhaled corticosteroids, 137, 182-183
 with pharmacotherapy, 135t
 with pulmonary rehabilitation, 117, 117t, 118
 oxygen therapy and, 126
 questionnaires, 74
 Healthy Resources (organization), 304
 Heart disease. See *Cardiovascular disorders*.
 Heart-related symptoms of COPD, 59-60
 Heart sounds, 59-60, 255-256, 257
 Helium dilution technique, 68
 Hematocrit, 74, 127, 259, 260
 Hemoglobin, 75
 Hemoptysis, 56
 History, 54-57, 282
 of asthma/respiratory illnesses, 57
 of exacerbations, 57, 282
 of exposure to risk factors, 52t
 family history of COPD, 57, 83
 medical, 54-57, 84
 preoperative, 233
 of smoking, 57, 84
 Holding chamber, 214, 215, 217t
 Home care, 92, 93t
 for exacerbations, 287, 287t, 288t
 oxygen therapy, 126-128
 surveillance and oversight in, 264
 Hoover's sign, 58
 Hormone supplementation/replacement, 25, 261-262, 263t
 Hospice services, 92, 301
 referral for, 92, 93t
 Hospitalizations
 for acute respiratory failure, 300
 costs of, 25, 26, 28, 275
 discharge criteria, 287, 288t
 for exacerbations, 252, 275
 indications for, 287, 287t
 follow-up assessment, 288t
 reduction in
 with bronchodilators, 166, 171
 with corticosteroids, 190-192, 190
 Hounsfield units (HU), 78
 HRQOL. See *Quality of life, health related (HRQOL)*.
 Human growth hormone, 268-269
 Hypercapnic respiratory failure, 281, 283
 Hypercapnia, 46, 58-59, 127
 in exacerbations, 280-281, 280t
 hospitalization for, 287t
 Hypercarbia
 in advanced COPD, 38t
 in exacerbations, 280t
 Hyperglycemia, 284

- Hyperinflation, 38-42, 38t, 54
 assessing, 68-69, 68
 bronchodilator reduction of, 137, 138, 139, 166-169, 168, 169, 250
 dynamic hyperinflation, 38t, 39-42, 68-69, 137, 139, 166, 250
 in exacerbations, 275
 IC/TLC ratio and, 39-40
 positive vs negative effects of, 38-39
 radiographic signs of, 75-77, 76-77
 signs of, 58
 static hyperinflation, 38-39, 38t, 137, 139, 166
 surgery for, 235-240
- Hyperplasia
 of airway smooth muscle, 34, 141
 of submucosal glands, 32
- Hyperresponsiveness of airways, 24, 45
- Hypertension, 57, 256t
 in COPD patients, 57, 60
 diuretics for, 260
 pulmonary, 77, 255-257
 detection of, 79-80
 systemic, 257, 258, 260-261
 treatments for, 256-257, 260-261
- Hypochloremic alkalosis, 258, 260
- Hyponatremia, 258, 260
- Hypoxemia, 38t, 42-43, 248
 cyanosis from, 58
 in exacerbations, 280-281, 280t, 287t
 treating, 281, 286t
 hospitalization for, 287t
 hyperinflation and, 39
 life-threatening, 286t
 nutritional disorders and, 268
 pulmonary hypertension and, 255
 sleep disorders and, 266
 treatments for
 in exacerbations, 281, 286t
 mechanical ventilation, 286t
 oxygen therapy, 42, 246t, 258, 281
 surgery, 234
- Hypoxia, 46, 264
- IC. See *Inspiratory capacity*.
- IC/TLC (inspiratory capacity/total lung capacity), 39-40
- ICAM-1, 280t
- ICU admission, 287, 287t
- IL. See *Interleukins*.
- Immunizations. See *Vaccinations*.
- Immunoregulators, 220t
- Immunosuppression, 182
- Impotence, 269
- Incidence of COPD, 17-21
- Indacaterol, 141, 146t, 153-159
 adverse events, 155, 156
 agents/formulations, 146t, 153
 Arcapta Neohaler, 141, 146t, 153, 158
 Onbrez Beezhaler, 146t, 153, 159
 in combination with tiotropium, 174-175, 179t
- Indacaterol (*continued*)
 dosage, 141, 146t, 158-159
 European Union, 146t, 159
 United States, 146t, 158
 efficacy, 153-154, 153-158, 154, 155, 157, 158
 long-term safety and, 155-158, 157
 half-life, 153
 onset of action, 153-154, 154
 tolerability, 155
 vs other bronchodilators, 156-157
- Infections, COPD exacerbations and, 277-278, 278t, 279, 284-285, 289
- Inflammation, 34, 35t, 37, 43, 133, 219
 airflow limitation associated with, 34, 133, 193, 275
 in asthma, 34, 35t
 cells involved in, 34, 35t, 36t
 in COPD, 34, 35t, 37, 46, 60
 in COPD definition, 17, 247
 in exacerbations, 275, 278, 279, 280t
 future therapies based on, 219-221
 genetic factors in, 34
 inflammatory pattern, 34, 35t
 nutrition, effect on, 123-124
 phosphodiesterase inhibitors and, 210, 291
 smoking and, 43
 systemic inflammation, 60
- Inflammatory cells, 34, 35t, 36t
- Influenza, COPD exacerbations and, 218, 284, 289
- Influenza vaccination, 90, 136, 218, 222t, 289, 289t
- Inhalation devices, selection of, 214-218, 216t-217t
- Inhaled agents. See *Bronchodilators; Corticosteroids, inhaled*.
- Inhaled pharmacotherapy, preference for, 214
- Inhaled Steroids in Obstructive Lung Disease in Europe (ISOLDE) trial, 182-183, 186, 187, 188-189
- Intotropic agents, 258
- Insomnia
 in exacerbations, 282
 roflumilast and, 214, 292
 smoking cessation therapy and, 104, 106t, 107
- Inspiratory capacity (IC), 68, 68, 166
 assessing therapeutic effectiveness with, 139
 post-bronchodilator, 139, 166-169
 ratio to total lung capacity (IC/TLC), 39-40
 tiotropium and, 166-169, 168, 169
- Inspiratory reserve volume (IRV), 54, 68
- INSPIRE trial, 290, 293-295
- Inspiry!, 142t
- Intensive care unit (ICU), 287, 287t
- Interleukins, 35t, 46
 COPD exacerbations and, 279, 280t
 IL-4, 279
 IL-5, 279
 IL-6, 35t, 278, 279, 280t
 IL-8, 35t, 46, 219, 279, 280t
 inhibitors of, 219
- Interventions. See *Management of COPD*.
- Intubation, 285, 286, 300
- Invasive mechanical ventilation, 286, 286t

Ipratropium, 160-162, 161t
agents/formulations, 161t, 194t
 Atrovent (ipratropium bromide), 161t
 Berodual, Duovent, and nebulizer liquid, 194t
 Combivent and DuoNeb, 194t
in combination
 with albuterol (Combivent; DuoNeb), 160, 174, 176-177, 194t, 196-197
 with fenoterol (Berodual; Duovent; nebulizer liquid), 194t
 with salmeterol, 174, 178
dosage, 160, 161t, 172
duration of action, 160
effectiveness, 160-162, 162, 196-197
 in acute bronchospasm, contraindication for, 160
 on dynamic hyperinflation, 138
key points, 172
onset and duration of action, 160
in reversibility testing, 66t
vs formoterol, 149-150, 151
vs metaproterenol, 160-162, 162
vs tiotropium, 164-166, 165
IRV (inspiratory reserve volume), 68, 68
Isotherine (Bronkosol; Bronkometer), 143t
ISOLDE (Inhaled Steroids in Obstructive Lung Disease in Europe) trial,
 182-183, 186, 187, 188-189
Isoproterenol (Isuprel), 143t
Isuprel (isoproterenol), 143t

Jet nebulizers, 153, 216t
Jugular vein, 59, 257

Kco (DLCO/VA), 69
Keenan, Joseph, 13
Ketoconazole, 214

LABAs. See *Long-acting β_2 -agonists (LABAs)*.
Laboratory tests. See *Tests for COPD patients*.
Laurell, Carl-Bertil, 45
Left-heart failure, 257-258
 COPD exacerbations and, 278t
Leukotriene inhibitors, 219
Leukotrienes, 269
Levalbuterol (Xopenex), 140, 144t
Libido, loss of, 269
Lifestyle changes, 85, 115-116. See also *Nonpharmacologic therapy*.
Liver enlargement, 59-60
Living will, ventilation decisions and, 286
Lobectomy, 234
Long-acting β_2 -agonists (LABAs), 90, 141, 146t, 158-159, 250. See also
 specific agents.
 action mechanisms, 134, 135
 adverse effects, 141, 159
 agents/formulations, 141, 146t
 arformoterol, 146t, 150-152
 formoterol, 146t, 149-153, 159
 formoterol fumarate inhalation solution (FFIS), 146t, 152-153
 salmeterol, 141-149, 159
 ultra-long-acting (indacaterol), 146t, 153-159

Long-acting β_2 -agonists (LABAs) (*continued*)
cautions for, 152
in combination
 with inhaled corticosteroids, 91-92, 187, 193-207, 223, 251, 265
 with ipratropium, 174, 178
 with theophylline, 251
dosage, 141, 146t, 147, 149-150, 152, 153, 158-159
indications for, 141, 159
onset and duration of action, 141-147, 149, 153
Losartan, 261
Lung
 hyperinflation of. See *Hyperinflation*.
 normal vs. diseased, histology of, 40-41
 “Lung age,” 85, 88, 89
The Lung Association, 306
Lung cancer, 264, 265
Lung density, CT scan of, 78-79
Lung function. See also *Gas exchange abnormalities*.
 aging impact on, 21, 62
 assessing/tests for, 60-70
 bronchodilator combinations and, 196-197, 251
 corticosteroid/bronchodilator combinations and, 195-197, 252
 corticosteroid impact on, 182-186
 pharmacotherapy impact on, 135t
 phosphodiesterase-4 inhibitors and, 211
 post-bronchodilator, 64-66, 137-139, 138, 250
 anticholinergics, 166-169, 171
 β_2 -agonists, 141, 197
 roflumilast and, 211, 212t, 291
 surgical impact on, 234
 theophylline and, 207
 tiotropium and, 166-169, 168, 169, 290
Lung Health Study, 95, 96, 183, 187
Lung parenchyma, destruction of, 133, 221
Lung resection, 233, 234
Lung surgery. See *Surgical therapy*
Lung transplantation, 240-242, 241t
Lung volume-reduction surgery (LVRS), 235-240, 238-239
 referral for, 93t
Lung volumes
 in COPD diagnosis, 68-69, 68
 measuring, 68-69
 tiotropium and, 166-169, 168, 169

M catarrhalis, 278, 284
MacNee, William, 13
Macrophages, 35t, 36t, 43
 in exacerbations, 279, 280t, 291
Malnutrition, 46, 122-124, 267-269
Management of COPD, 83-94, 85, 86, 245-254. See also *specific therapeutic approaches*.
 algorithm for, 85
 bronchodilator role in, 137-139, 250-251
 comorbid conditions, 255-274
 consultation and referral, 92, 93t
 COPD definition, 245-247
 end-stage disease, 299-302

Management of COPD (*continued*)

exacerbation management, 281-287. See also *Exacerbations*.
exacerbation prevention, 289-295
exercise program, 91, 116-117, 120-121
general approach, 83-94
goals of, 115, 133-134, 248-250, 289
guidelines, 85, 245-254, 246t
web-based updates, 245
multicomponent/heterogenous disease presentation, 88-89, 90
noninvasive ventilation, 127-128, 253
nonpharmacologic therapy, 115-132
nutrition, 122-125
overview of, 84, 85, 133-137, 222-223, 246t
pharmacologic therapy, 133-232, 250-252. See also *Pharmacologic therapy*.
bronchodilators, 137-178, 250-251
combination therapy, 251-252
corticosteroids, 178-193, 251
future therapies, 219-221
integration with patient care, 221-223, 222t
key points on, 135t, 222-223, 246t
stepped-care approach, 221-223, 222t
triple therapy, 252
prevention and early detection, 83-89
primary care physicians in, 13, 14-15, 25, 27, 83, 84, 91, 92
pulmonary hygiene, 91
pulmonary rehabilitation, 115-125, 252
response to treatment, assessment of, 139, 248-250, 250t
screening questionnaire, 86t-87t
severe COPD, 91-92
smoking cessation and, 95-114
stable COPD, 90-91
surgical therapy, 233-244
team approach, 91-92
Matrix metalloproteinases (MMPs), 221, 259
Maxair (pirbuterol), 140, 144t
MDIs (metered dose inhalers), 214, 215, 217t, 218
Mechanical ventilation, 286, 286t, 300. See also *Ventilation support*.
Medical care, costs. See *Costs of COPD*.
Medical history, 54-57, 83-84. See also *Diagnosis*.
Medical Outcomes Study Short Form 36 (SF-36), 149
Medical problems, COPD-related. See *Comorbid conditions*.
Medical Research Council (MRC) Dyspnea Scale, 55, 55t, 248
Medications. See *Pharmacologic therapy*.
Memory, decline in, 264
Men
mortality rates from COPD, 19-20, 19
nomogram for predicting lung age, 85, 88
prevalence of COPD in, 18
Menopause, 24-25
Mental health, 57, 60
disorders of, 256t, 262-264
referrals for, 92, 93t
status, assessment in exacerbations, 282
Metabolic acidosis/alkalosis, 71, 258, 260
Metabolism, increased, 46, 47t
Metaprel, 144t

Metaproterenol, 140, 144t
vs ipratropium, 160-162, 162
Metaproterenol sulfate, 144t
Metered dose inhalers (MDIs), 214, 215, 217t, 218
Methylxanthines, 207-210, 208t. See also *Theophylline*.
action mechanisms, 134, 135, 207
benefits vs risks, 207, 210
in combination with other bronchodilators, 175, 251
drug-disease/drug-drug interactions, 207, 209t
indications for, 207, 210
key points, 210
side effects, 207
Metoprolol, 259
MMPs (matrix metalloproteinases), 221, 259
Modified Borg Scale, 55, 55t
Monitoring. See *Follow-up and monitoring*.
Monoamine oxidase inhibitors, cautions for, 152
Monocytes, 291
Moraxella catarrhalis, 278, 284
Morbidity, COPD-related
comorbid conditions and, 60
corticosteroids and, 190-192, 190
costs of, 25, 26
systemic effects and, 60
Mortality
all cause, in TORCH trial, 202-207, 204
cardiovascular risks/causes, 173, 258, 259
for chronic smokers, 95
comorbid conditions and, 60, 258
COPD as leading cause of, 20
lung surgery and, 234, 240, 241, 242
smoking and, 95
Mortality from COPD, 19-21, 19, 20
body mass index (BMI) and, 42, 122-123, 123, 277
costs related to, 25, 26
developed vs developing countries, 17-18
exacerbations and, 275, 277
gender and, 19-20, 19
malnutrition associated with, 122-123, 123
predictors of
BMI, 46
BODE Index, 42
IC/TLC, 42
reducing
with corticosteroid/bronchodilator combinations, 134
with corticosteroids, 134, 190-192, 190
systemic effects and, 60
TORCH trial results, 202-207, 205, 206
Motivation for smoking cessation, 95, 98t, 99-101, 100t
MRC (Medical Research Council) Dyspnea Scale, 55, 55t
Mucociliary dysfunction, 90
Mucolytic agents, 219, 220t, 267
Mucus hypersecretion, 24, 32, 33, 219
in exacerbations, 279, 280t, 285
treatment of, 285
Multicomponent nature of COPD, 88-89, 90

- Muscarinic receptors, 134, 135, 160
subtypes, 162-163, 163
- Muscle wasting and dysfunction, 46, 47t, 60, 122-124, 261-262
consequences of, 122
measurement of, 72, 124
pathogenesis of, 123-124
treatment of, 261-262, 268-269
- Muscles. See also *Muscle wasting and dysfunction*.
airway smooth muscle
bronchodilator impact on, 134, 135, 141
hyperplasia of, 34, 141
muscarinic receptor subtypes on, 162-163, 163
deconditioning of, 46, 57, 116, 261
effect of pulmonary rehabilitation on, 115, 116
muscle mass, measurement of, 124
peripheral muscle metabolism, 46, 47t
respiratory muscles
accessory muscles, 58, 282
exercise training, 121
function testing, 72
systemic corticosteroids and, 182
skeletal muscle dysfunction, 122-124, 261-262
strength
decreased, nutritional depletion and, 46, 122
increased, with theophylline, 207
- Musculoskeletal disorders, 256t, 261-262
- Myocardial infarction, 173, 258
- Myopathy, 182
- N*-acetylcysteine, 221
- Narcotics, 220t, 287t
- National Emphysema/COPD Association (NECA), 305
- National Emphysema Foundation, 305
- National Emphysema Treatment Trial (NETT), 235, 236, 238-239
- National Heart, Lung, and Blood Institute, 83, 245, 305
- National Institute of Clinical Excellence (NICE), 245, 249t
- National Jewish Health Lung Line, 305
- National Lung Health Education Program (NLHEP), 83
- Natural history of COPD, 44
- Nausea, 207, 212, 214, 292
- Nebulizer agents, 194t
- Nebulizer devices, 214, 215, 216t
- Nebulizer therapy, for exacerbations, 284
- NECA (National Emphysema/COPD Association), 305
- Neck vein distention, 59
- NETT (National Emphysema Treatment Trial), 235, 236, 238-239
- Neulin Depot, 208t
- Neutrophil elastase, 221
- Neutrophils, 35t, 36t, 43
in COPD exacerbations, 279, 280t
inhibition of recruitment/function, 141, 219, 291
oxidant production by, 221
- NICE (National Institute of Clinical Excellence), 245, 249t
- Nicotine dependence, Fagerstrom test for, 104, 105t
- Nicotine-replacement therapy, 103-104, 106t. See also *Smoking cessation*.
delivery systems, 103
prescribing information, 106t
side effects, 104
- Nicotinic acetylcholine receptor partial agonist. See *Varenicline*.
- Nitrates, 259
- Nitric oxide
inflammation and, 35t
inhaled, for pulmonary hypertension, 257
- NLHEP (National Lung Health Education Program), 83
- Nocturnal Oxygen Therapy Trial (NOTT), 126, 126
- Nomograms for predicting lung age, 85, 88, 89
- Noninvasive mechanical ventilation, 252, 285-286
- Noninvasive positive pressure ventilation (NPPV), 127-128, 252, 285-286
- Nonpharmacologic therapy, 115-132. See also *Pulmonary rehabilitation*.
oxygen therapy, 126-128
pulmonary rehabilitation, 115-125
- Nortriptyline, 263
- NOTT (Nocturnal Oxygen Therapy Trial), 126, 126
- Nuclear-perfusion imaging, 259
- Nutrition, 122-125
depletion of, 46, 122
disorders of, 267-269
emphasis on, 91
inflammatory response and, 123
interventions, 46, 122-125
nutritional status
assessment of, 124
as risk factor, 122-123, 123
nutritional supplementation, 124-125, 263t, 268-269
- Nutritional disorders, 122-124, 267-269
mechanisms of, 268, 268
symptoms of, 267
treatment of, 268-269
- Obese patients, 123, 124
- Obstructive sleep apnea, 266
- Occupational risk factors for COPD, 52t, 57
- Occupational therapists, 119
- Older patients. See also *Age*.
aerosol device use by, 215
cognitive decline in, 264
COPD risk/prevalence and, 19, 21, 247
hormone supplementation/replacement for, 261-262, 263t
- Omega-3 fatty acids, 269
- Onbrez Beezhaler (indacaterol), 146t, 153, 159
- Osteoporosis, 57, 60, 262
comorbid with COPD, 256t, 262
corticosteroids and, 182
management in COPD, 262, 263t
- Overinflation. See *Hyperinflation*.
- Oxidative stress, 34, 35t, 37, 60, 221
exacerbations and, 278-279
- Oximeters/oximetry, 70, 282, 283
- Oxis, 146t
- Oxitropium bromide (Oxivent), 161t
- Oxivent (oxitropium bromide), 161t
- Oxygen, partial pressure in arterial blood (PaO₂), 60, 70, 127, 128
- Oxygen saturation
in exacerbations, 282, 283
measuring, 70, 71, 282, 283

Oxygen therapy, 91, 126-128, 136. See also *Ventilation support*.

air travel and, 128

during exercise, 126-127

evaluation for, 93t

goal of, 127

indications for, 126-127, 246t

cardiovascular disorders, 256-257, 258

exacerbations, 281, 283

hypoxemia, 42, 281

pulmonary hypertension, 127, 256-257

right-heart failure, 258

sleep disorders, 266

long-term, 127-128

Nocturnal Oxygen Therapy Trial (NOTT), 126, 126

portable oxygen, 127

in stepped-care approach to treatment, 222t

testosterone levels, impact on, 269

Oxyhemoglobin saturation, 282, 283

Palliative care, 300, 301

Palpitations, 159

Panacinar (panlobular) emphysema, 32

Panlobular emphysema, 32, 79

Paroxysmal abdominal breathing, 282

Pathogenesis of COPD, 34-43, 37

Pathology of COPD, 31-34, 33. See also *Pathophysiology of COPD*.

chronic bronchitis, 31-32, 33, 40-41

emphysema, 32, 33

exacerbations, 279, 280t

future therapies and, 219-221

histopathology, 40-41

pathogenic mechanisms, 37

small-airways obstruction, 32-34, 37-38, 52

Pathophysiology of COPD, 31-50

airway inflammation, 34, 35t, 37, 38, 43-44

inflammatory cells, 35t, 36t

definition of COPD and, 31, 247

factors in development and progression, 43-46

muscle wasting and dysfunction, 46, 47t

natural history of COPD, 44

pathogenesis, 34-43, 37

pathology, 31-34, 33

chronic bronchitis, 31-32, 33, 38, 40-41

emphysema, 32, 33, 40-41

histopathology, 40-41

small-airways obstruction, 32-34, 37-38, 52

progression of, 44

respiratory physiologic alterations, 34-43, 37, 38t

airflow limitation, 37-38, 39t, 40-41

gas-exchange abnormalities, 42-43

hyperinflation (static and dynamic), 38-42

reversibility with bronchodilators, 42, 43

systemic consequences of COPD, 46, 47t, 60

Patient

general approach to, 83-94

integration of pharmacologic therapy with, 221-223, 222t

motivation for smoking cessation, 95, 98t, 99-101, 100t

relationship with primary care physician, 83, 91

Patient education, 85

on aerosol device usage, 214-215

on end-stage disease/decisions, 299-300

on exacerbation recognition and prevention, 289t

on exacerbation treatment, 91

in pulmonary rehabilitation, 121-122

treatment decisions and, 221-223

PCPs. See *Primary care physicians*.

PDE₄ inhibitors. See *Phosphodiesterase-4 (PDE₄) inhibitors*.

Peak expiratory flow (PEF), 64

Peak expiratory flow rate (PEFR), 141

PEF (peak expiratory flow), 64

Percussion of the chest, 59

Performist (formoterol fumarate inhalation solution), 146t, 152-153

Perfusion. See *Ventilation-perfusion (\dot{V}/\dot{Q})*.

Peripheral edema, 59, 127, 257, 260

Peripheral vascular disease, 57, 60

Peripheral vasodilation, 59

Pharmacologic stress testing, 259

Pharmacologic therapy, 133-232. See also *specific therapies*.

action mechanisms, 134-137, 135

bronchodilation, production of, 134, 135

combined therapies, 251-252

indications for, 246t

rationale for, 134, 135t

COPD stages, therapy for each stage, 136

device selection in aerosol therapy, 214-218, 216t-217t

effects of, 135t

future therapies, 219-221

goals of, 133-134, 248-250

inhaled pharmacotherapy, preference for, 214

integration with patient care, 221-223, 222t

key points, 135t, 246t

limitations of, 133

monotherapy, 134, 246t

overview, 133-137, 135t, 222-223, 246t

for smoking cessation, 103-111

specific therapies

bronchodilators, 137-178, 250-251

bronchodilator combinations, 174-178, 251

corticosteroids, 178-193, 251

corticosteroid/bronchodilator combinations, 193-207, 251, 252

methylxanthines, 207-210

other, 218-219, 220t

phosphodiesterase inhibitors, 210-214

triple therapy, 252

stepped-care approach, 221-223, 222t

TORCH trial results, 134, 192, 202-207

Phlebotomy, 259

Phosphodiesterase-4 (PDE₄) inhibitors

nonselective (methylxanthines), 207-210

selective, 210-214. See also *Roflumilast (Daliresp)*.

Phyllocontin, 208t

Physical activity. See *Exercise*.

Physical examination, 58-60, 84

for exacerbations, 282-283

Physical therapist, 92, 119

Physicians, 91-92, 93t, 119
 primary care. See *Primary care physicians (PCPs)*.
 referral to. See *Referral*.

Physiologic alterations in COPD, 34-43, 38t

PiM allele, 45

Pirbuterol (Maxair), 140, 144t

PiZ/PiZZ alleles, 45

Plethysmograph, 68

Pneumectomy, 234

Pneumonia, 57, 201, 205, 295
 COPD exacerbations and, 278, 278t
 immunization for, 90, 218, 289, 289t
Streptococcus pneumoniae, 278, 284

Pneumothorax, 57, 278t

Pollution, air. See *Air pollution*.

Polycythemia, 74-75, 127

Polyunsaturated fatty acids, 269

Post-bronchodilator FEV₁/FVC ratio, 37, 39t

Prednisolone, 66, 284

Prednisone, 182

Prevalence of COPD, 17-21. See also *Risk factors for COPD*.
 age and, 19, 21
 COPD definition and, 21, 247
 in developing vs developed countries, 17-19, 21, 22
 gender and, 18, 20, 24
 global, 18, 21
 increase in, 14
 smoking and, 18, 22-23, 22
 underestimation of, 17-18

Prevention and early detection, 83-89
 benefits of, 83, 84
 of comorbid conditions, 255
 of exacerbations, 289-295
 risk factors and, 83-84
 screening questionnaire, 86t-87t
 spirometry for at-risk individuals, 84-85

Primary care physicians (PCPs)
 comorbid condition management by, 255
 COPD management by, 13, 14-15, 25, 27, 83, 84, 91, 92
 COPD, reasons for concern about, 14-15, 83
 COPD team, role in, 92
 exacerbation management by, 91
 follow-up and monitoring by, 73
 general approach to COPD patient, 83-94
 motivation for smoking cessation by, 85, 100
 positive attitude, importance of, 83
 referral to specialists, 73-74, 92, 93t
 relationship with patient, 83, 91
 smoking, inquiring about, 96-99, 98t

Progression of COPD. See *Disease progression*.

Progressive symptom-limited exercise testing, 71

ProMeta, 144t

Prostacyclin analogs, 257

Protease inhibitors, 24, 45, 221

Proteases, 24, 45, 221, 259
 in exacerbations, 279

Protein intake, 261

Protein metabolism, changes in, 46, 47t, 124

Proteinases, 34, 37

Proventil, 140, 142t

Proximal airways, 38

Pseudodementia, 264

Psychiatric morbidity, 57, 60

Psychologists, 119. See also *Mental health*.

Public health intervention, 14

Pulmicort. See *Budesonide*.

Pulmonary arterial hypertension, 255

Pulmonary arterial pressure, 77

Pulmonary Channel Healthcommunities.com, 305

Pulmonary Education and Research Foundation (PERF), 305

Pulmonary embolism, 278t

Pulmonary function tests, 60-70

Pulmonary hygiene, 91

Pulmonary hypertension, 77, 79-80, 255-257
 in COPD exacerbations, 280t
 electrocardiography in, 256, 256t
 oxygen therapy for, 127, 256-257
 treatment of, 256-257

Pulmonary obstruction. See *Airflow obstruction*.

Pulmonary parenchyma. See *Lung parenchyma*.

Pulmonary rehabilitation, 115-125, 252
 benefits of, 46, 115, 116-119, 117t, 252
 cautions for, 120
 combined with pharmacotherapy, 117
 components of, 119-125
 controlled trials on, 116-119, 117t
 deconditioning and inactivity and, 46, 115, 116
 definition of, 115
 in end-stage disease, 300
 for exacerbation prevention, 118, 289t
 exercise training in, 116-117, 118, 120-121
 indications for, 120, 246t
 individual tailoring of, 119
 long-term effectiveness of, 125
 multidisciplinary team in, 119
 nutritional therapy, 122-125
 outcome assessment for, 125
 patient education in, 121-122
 psychosocial and behavioral intervention in, 122
 settings for, 125
 skeletal muscle function and, 122-124
 specialist referrals in, 93t
 in stepped-care approach, 222t

Pulmonary specialist, referral to, 92, 93t

Pulmonary vascular pressure testing, 73

Pulse oximetry, 282, 283

Purse-lipped breathing, 58

Purulent sputum. See *Sputum production*.

Qtc interval, prolongation of, 152

Quality of life (QOL)
 COPD threat to, 26, 115, 116
 in end-stage COPD, 299
 exacerbations and, 91, 289

Quality of life (QOL) (*continued*)

- health-related (HRQOL)
 - bronchodilators and, 139, 147, 149
 - combination therapy and, 196, 199
 - surgical therapy and, 234
 - improving, 15
 - with bronchodilators, 139, 147, 149, 150, 153, 156, 160, 165, 166, 171
 - with combination therapy, 196, 199, 203, 252, 295
 - with inhaled corticosteroids, 182
 - with pulmonary rehabilitation, 116-117
 - with surgery, 234
 - with tiotropium, 290
 - inquiry about, 57
 - measures of, 74
 - monitoring, 74
 - nutritional depletion and, 46
 - questionnaires, 74
 - sleep disorders and, 266
- Questionnaires, 74
- assessment of symptomatic benefit from treatment, 250t
 - COPD screening, 86t-87t
 - CRDQ, 74, 118, 147
 - SF-36 (Medical Outcomes), 149
 - SGRQ, 74, 118, 149, 150, 156, 157, 158, 165, 165, 171, 182, 203
- Quibron-T, 208t
- Qvar, 184t

Race

- prevalence rates for COPD and, 18, 24
- protease inhibitor (PiM, PiZ, PiZZ) alleles and, 45

Radiography, 75-80

- computed tomography (CT), 78-79, 79, 236t
- echocardiography, 79-80
- plain chest, 75-77, 76-77, 236t
- for exacerbations, 282-283

Raloxifene, 263t

RANTES, 280t

Reactive airway disease, 83

Reactive oxygen species, 221

Recombinant human growth hormone, 268-269

Referral, 83, 92, 93t

- to specialists, 73-74, 83, 92
- indications for, 92, 93t

Rehabilitation. See *Pulmonary rehabilitation*.

Residual volume (RV), 54, 68, 68

Resources on COPD, 303-306

Respid, 208t

Respiratory acidosis, 43, 46, 71, 255

- hospitalization for, 287t
- mechanical ventilation for, 286t

Respiratory failure, 70, 136, 299. See also *Ventilation support*.

- end-of-life decisions and, 299-301
- from exacerbations, 277

Respiratory infections. See *Bacterial infections; Viral infections*.

Respiratory muscles

- accessory muscles of respiration, 58, 282
- corticosteroid use and, 182

Respiratory muscles (*continued*)

- function testing, 72
 - training of, 121
- Respiratory nurse, 300
- Respiratory physiologic alterations and abnormalities, 34-43, 38t
- Respiratory rate, 58
- Respiratory signs of COPD, 58-59
- Respiratory stimulants, 220t
- Respiratory therapist, 92, 119
- Rhinalar, 185t
- Rhinovirus, 278
- Rhonchi, 59
- Rib fractures, 262, 278t
- Right-heart failure (cor pulmonale), 59, 256t, 257-258
- COPD exacerbations and, 278t, 282
 - diuretics and, 260
- Right ventricular function, assessment of, 73, 79-80
- Right ventricular hypertrophy, 77
- electrocardiography of, 256, 256t
- Risk factors for COPD, 21-25, 43-45, 83-84
- age/aging, 23, 83
 - air pollution, 23, 45, 83
 - airway hyperresponsiveness, 45
 - demographic factors, 24, 45
 - environmental pollution, 83
 - estrogen and, 24-25
 - gender, 24-25
 - genetic factors/family history, 23-24, 45, 83
 - history of exposure, 52t, 57, 83
 - occupational risk factors, 52t
 - smoke/smoking, 21-23, 22, 52t, 83, 133
- Roflumilast (Daliresp), 211-214, 291-292
- adverse effects, 212, 214, 292
 - clinical trials, 211-213, 212t, 213t, 291-292
 - dosage, 212
 - drug interactions, 214
 - effects, 211, 291
 - on exacerbations, 211-212, 213t, 289t, 291-292
 - on FEV₁, 211, 212t
 - indications for, 211, 212, 291
 - approved for COPD and exacerbations, 211, 289, 291
 - not intended for acute bronchospasm, 291, 292
- Rotahaler, 184t
- RV (residual volume), 68
- S pneumoniae*, 278, 284
- Saint George's Respiratory Questionnaire. See *SGRQ*.
- Salamol, 142t
- Salbutin, 142t
- Salbutamol, 66t, 142t-143t
- Salmeterol, 141-149, 146t. See also *Fluticasone/salmeterol (Advair/Advair Diskus)*.
- in combination
 - with anticholinergics
 - ipratropium, 174, 178
 - tiotropium, 175-178, 181

Salmeterol, in combination (*continued*)
with inhaled steroid fluticasone (Advair), 91-92, 149, 193-197, 194t, 292-295, 294
with theophylline, 175, 180
in TRISTAN study, 183, 195-196, 195
dosage, 146t, 147
effects and efficacy of, 147-149, 148
formulations
salmeterol/fluticasone (Advair/Advair Diskus), 194t
salmeterol xinafoate (Serevent; Serevent Diskus), 141, 146t
side effects, 175
vs indacaterol, 156-157
vs theophylline, 147
vs tiotropium, 147-149, 148, 166
Salmeterol/fluticasone. See *Fluticasone/salmeterol (Advair/Advair Diskus)*.
Salmeterol xinafoate (Serevent, Serevent Diskus), 141, 146t
Screening for COPD, 83-84
questionnaire for, 86t-87t
Secretions, mobilization and clearance of, 285. See also *Mucus hypersecretion*.
Sedentary lifestyle, 46, 60
Seizures
bupropion and, 107
theophylline and, 207
Selective serotonin reuptake inhibitors (SSRIs), 263
Self-paced exercise tests, 72
Self-report surveys, 18
Seretide/Advair combination formulations, 194t
Serevent (salmeterol xinafoate), 141, 146t. See also *Salmeterol*.
Serevent Diskus, 141
Serum albumin level, 277
Severe COPD, management of, 91-92, 127, 136. See also *Surgical therapy*.
end-stage disease, 299-302
Severity classification and staging. See *Stages of COPD*.
Sexual dysfunction, 256t, 269
SF-36 (Medical Outcomes Study Short Form 36), 149
SGRQ (St George's Respiratory Questionnaire), 74, 118
improvements with bronchodilator use, 149, 150, 156, 157, 158, 165, 165, 171
improvements with combination therapy, 203
improvements with inhaled corticosteroids, 182
SHINE trial, 201-202
Short-acting β_2 -agonists, 90, 140-141, 159. See also *specific agents*.
indications for, 140, 159, 284
onset and duration of action, 140
specific agents and dosages, 140, 142t-145t
Shortness of breath. See *Dyspnea*.
Shuttle-walking tests, 72, 121
Sildenafil (Viagra), 257, 269
"Silent zone," 38
6-Minute walk, 42, 72, 121
Skeletal muscle deconditioning, 46, 116, 261
Skeletal muscle dysfunction, 60, 256t, 261-262. See also *Muscle wasting and dysfunction*.
Sleep apnea, 73
Sleep disorders, 57, 73, 256t, 265-267
factors associated with, 266
treatment of, 266-267

Sleep hygiene, 267
Sleep studies, 73, 266
Slo-Bid, 208t
Slo-Phyllin, 208t
Small airways
disease (bronchiolitis), 52
inflammation of, 43-44, 52, 133
obstruction of, 32-34, 37-38
vital capacity as indicator of function, 67-68
Smoke
as COPD risk factor, 21-23, 52t, 83
from home cooking and heating fuels, 23, 52t
inflammation and, 43
reactive oxygen species in, 221
"Smoker's cough," 51, 56
Smoking
addictiveness of, 95
airflow limitation with, 44-45, 44
airway bacterial colonization and, 278
airway inflammation and, 34, 43-44
cancers and, 264-265
cardiovascular risk and, 258
COPD pathogenesis and, 37, 43-44
COPD prevalence rates and, 18, 22-23, 22
as COPD risk factor, 21-23, 22, 44-45, 52t, 83, 133
emphysema and, 32
Fagerstrom test for nicotine dependence, 104, 105t
FEV₁ and, 44, 44, 45
as "fifth vital sign," 84
gender and, 22-23, 22
genetic/susceptibility factors, 44-45
history, inquiry about, 57, 84
increase in, 22-23
intervention strategies, 96-111
lung inflammation and, 43-44
osteoporosis and, 263t
percentage of smokers progressing to COPD, 95
premature deaths due to, 95
pulmonary rehabilitation eligibility and, 120
signs of, on physical examination, 58
treaty on tobacco control, 23
Smoking cessation, 15, 90, 95-114
algorithm for, 97
alternative interventions, 15
assisting in, 98t, 99
barriers to, 99-101
benefits of, 90, 95, 96, 133
encouragement for, 98-101
follow-up in, 98t, 99, 101, 102t, 287
guidelines for, 96, 98t, 100, 100t, 101
impact of/necessity for, 90, 133
motivation for, 95, 98t, 99-101, 100t, 102t
in osteoporosis management, 263t
pharmacotherapy for, 103-111
bupropion, 103, 104-107, 106t
nicotine-replacement, 103-104, 106t

- Smoking cessation, pharmacotherapy for (*continued*)
 - prescribing information, 106t
 - side effects/cautions, 104, 107, 111
 - varenicline (Chantix), 103, 107-111, 108, 110
 - prior to surgeries, 234
 - quit date, setting, 98t, 99
 - recommending, 96, 97, 98-99, 98t
 - relapse prevention, 101-102, 102t
 - strategies for, 96-111
 - five A's, 96, 98t
 - five R's, 100, 100t
 - pharmacotherapy, 103-111
 - relapse prevention, 101-102, 102t
 - success rates for, 103
 - support for, 95, 99, 101
 - weight gain and, 101, 102t
 - withdrawal symptoms, anticipating and treating, 99, 100, 102t
- Smooth muscle, airway
 - bronchodilator impact on, 134, 135, 141
 - hyperplasia of, 34, 141
 - muscarinic receptor subtypes on, 162-163, 163
- Social workers, on pulmonary rehabilitation team, 119
- Societal burden of COPD, 25-26, 26, 28
- Socioeconomic status, as risk factor, 24, 45
- Spacers in aerosol devices, 159, 214, 217t
- Specialist care, referral for, 73-74, 92, 93t
 - indications for, 73-74, 92, 93t
- Spiriva. See *Tiotropium*.
- Spirometry, 61-64, 246t
 - in assessment of therapy, 134
 - for at-risk individuals, 84-85
 - baseline, 134
 - in COPD diagnosis, 51, 61-64, 133, 134, 246t
 - COPD staging/classification based on, 37, 39t, 61, 62, 85, 247-248, 249t
 - in exacerbation monitoring/evaluation, 283
 - impaired airflow values, 62-64, 63, 133
 - importance of, 84-85, 134
 - indices derived from, 61, 62
 - normal, 61-62, 62
 - preoperative, 233
 - reversibility testing, 64-66, 66t
 - volume plateau in, 62-63
- Sputum production, 32, 51, 52t, 56
 - change in color, 56
 - chronic, 52t
 - in chronic bronchitis, 31-32, 51, 56
 - cough and, 56
 - in exacerbations of COPD, 276, 278, 284
 - purulent, 56, 252
 - antibiotics for, 218
 - bacterial species in, 278
 - in exacerbations, 219, 252, 276, 284
 - as symptom, 18, 56
- SSRIs (selective serotonin reuptake inhibitors), 263
- Stable COPD, management of, 90-91
- Stages of COPD, 39t, 62, 222t, 249t
 - based on FEV₁/FVC ratio, 39t, 62, 136, 222t
 - based on predicted FEV₁, 39t, 136, 222t, 247-248, 249t
 - based on spirometry, 39t, 62, 85, 247-248, 249t
 - stage 0: At Risk, 62
 - stepped-care approach based on, 136, 221, 222t
- Static hyperinflation. See *Hyperinflation*.
- Static lung volumes, 68-69, 68
- Steady-state exercise tests, 72
- Stepped-care approach, 221-223, 222t
- Steroid myopathy, 72
- Steroids. See also *Corticosteroids*.
 - anabolic, 46, 268
 - replacement therapy, 25, 261-262, 263t
- St George's Respiratory Questionnaire. See *SGRQ*.
- Strength training, 121
- Streptococcus pneumoniae*, 278, 284
- Stress testing, 259
- Stroke, 173
- Suicidal ideation/behavior
 - roflumilast and, 214, 292
 - varenicline and, 111
- SUN trial, 201-202
- Sunflower oil, 269
- Support groups, 122
- Surgical therapy, 233-244
 - complications and risks, 233
 - reducing, 234
 - evaluation for, 136
 - mortality from, 234, 240, 241, 242
 - patient selection for, 233, 234, 236t-237t
 - postoperative lung function, reduction in, 234
 - preoperative assessment, 233
 - preoperative spirometry, 233
 - smoking cessation prior to, 234
 - in stepped-care approach to treatment, 222t
 - surgeries for COPD
 - bullectomy, 234-235, 236t-237t
 - lung transplantation, 240-242, 241t
 - lung volume-reduction (LVRS), 235-240, 238-239
 - surgeries in COPD patient, 233-234
 - lobectomy, 234
 - lung resection, 233, 234
- Sustained-release bupropion. See *Bupropion*.
- Symbicort. See *Budesonide/formoterol (Symbicort)*.
- Symptoms of COPD, 52t, 54-57
 - chest pain and tightness, 56-57
 - chronic bronchitis, 51
 - cough, 18, 51, 56
 - dyspnea, 18, 51, 52t, 54-55, 55t
 - evaluation of, 54-57
 - of exacerbations, 275, 276, 277
 - osteoporosis, 57
 - progression of, 43-46
 - questionnaire for assessing benefit from therapy, 250t

- Symptoms of COPD (*continued*)
 reducing or relieving, 250. See also *Management of COPD*.
 bronchodilators, 137, 139
 pharmacologic therapy, 248-250
 pulmonary rehabilitation, 117
 self-report surveys, 18
 sleep disturbances, 57
 sputum production, 18, 51, 56
 time lag to, 84
 weight loss, 57
 wheezing, 18, 56
- Systemic corticosteroids. See *Corticosteroids, systemic*.
- Systemic effects of COPD, 17, 36, 47t, 60, 255-274
- Systemic hypertension, 257, 258, 260-261
- Systemic side effects of β_2 -agonists, 159
- T lymphocytes, 36t, 279, 280t, 291
- Tachyphylaxis, 140
- Tachypnea, 59
- TDI (transition dyspnea index), 157-158, 158, 197
- Team approach to COPD management, 91-92, 119
- Telmisartan, 261
- Terbutaline, 66t, 140, 145t
- Testosterone
 deficiency
 corticosteroid use and, 269
 osteoporosis and, 263t
 sexual dysfunction and, 269
 replacement/supplementation, 261-262, 263t
- Tests for COPD patients, 60-80
 α_1 -antitrypsin deficiency screening, 75
 arterial blood gases, 70
 bronchodilator reversibility, 64-66
 DLCO, 69
 exercise testing, 70-72
 flow-volume loops, 66-68
 health status questionnaires, 74
 peak expiratory flow, 64
 polycythemia assessment, 74-75
 pulmonary function tests, 60-70
 pulmonary vascular pressure and right ventricular function, 73
 radiography, 75-80
 required tests, 61-69
 respiratory muscle function, 72
 sleep studies, 73
 spirometry, 61-64
 static lung volumes, 68-69
 stress testing, 259
- The Lung Association, 306
- Theo-24, 208t
- Theo Dur, 208t
- Theochron, 208t
- Theochron SR, 208t
- Theofyllin, 208t
- Theolair, 208t
- Theophylline, 90, 207-210, 208t, 251
 action mechanisms, 135, 207
 agents and dosages, 208t
 anti-inflammatory effect of, 207, 251
 benefits vs risks, 207, 210
 in combination therapy, 175, 210, 251
 with salmeterol, 175, 180
 contraindicated for acute exacerbations, 284
 drug-disease/drug-drug interactions, 207, 209t
 adenosine, 259
 calcium antagonists and, 261
 cytochrome P-450 inhibitors, 263
 SSRIs, 263
 indications for, 207, 210, 251
 key points, 210
 long-acting, 208t
 short-acting, 208t
 side effects, 175
 vs salmeterol, 147
- Third National Health and Nutritional Examination Survey, 18
- Thoracic surgeon, referral to, 93t
- Thoracoscopic lung resection, 233
- Thoracotomy, 233
- Tidal volume (VT), 54, 72
- Tiotropium (Spiriva), 161t, 162-172, 250, 290
 action mechanisms, 160, 162-163, 163
 adverse effects
 cardiovascular risk, 173
 dry mouth, 172
 lack of, 163, 172
 approved for exacerbation reduction, 289, 290
 in combination, 290
 with exercise training, 117
 with indacaterol, 174-175, 179t
 with salmeterol or fluticasone/salmeterol, 175-178, 181
 dosage, 161t, 163, 172
 duration of action, 162-163
 effects, 162-163, 163, 172
 on exercise capacity/endurance, 168-169, 169, 170
 on lung volumes, 166-169, 168, 169, 290
 efficacy, 163-171, 164
 Dutch/Belgian Tiotropium Study Group, 164-166, 165
 exacerbation reduction, 166, 169, 171, 290, 293-295
 INSPIRE trial, 290, 293-295
 systemic review of, 169-170
 UPLIFT study, 171, 172, 173, 290
 half-life, 162-163
 key points, 172
 safety and tolerability, 171-172, 173
 vs fluticasone/salmeterol, 290, 293-295
 vs indacaterol, 156-157
 vs ipratropium, 164-166, 165
 vs LABA, 170
 vs salmeterol, 147-149, 148, 166
 TLC (total lung capacity), 68, 68, 139
 TLCO (diffusing capacity of carbon monoxide), 69
 TNF- α . See *Tumor necrosis factor alpha*.

- Tobacco-free initiative (treaty), 23
 Tobacco-related cancers, 264-265
 Tobacco smoke. See *Smoking*.
 TORCH trial, 134, 192, 202-207
 patient selection for, 202-203
 survival and mortality in, 192, 202-207
 all-cause mortality, 202-207, 204
 COPD mortality, 106, 202-207, 205
 Tomalate (Bitolterol), 140, 145t
 Total lung capacity (TLC), 68, 68, 139
 Towards a Revolution in COPD Health. See *TORCH trial*.
 Transition dyspnea index (TDI), 157-158, 158, 197
 Transplantation, lung, 240-242, 241t
 Travel, oxygen therapy during, 128
 Treadmill exercise, 117, 121
 Treadmill tests, 71
 Treatment. See *Management of COPD*.
 Treaty, tobacco-control, 23
 Treprostinil, 257
 Trial of Inhaled Steroids and Long-Acting β_2 -Agonists. See *TRISTAN*.
 Trials and studies. See *Clinical trials*.
 Triamcinolone (Azmecort), 185t
 bone density and, 183
 clinical studies, 183, 187, 188
 Tricuspid incompetence, 59-60
 Tricyclic antidepressants, cautions for, 152
 Triple therapy, 252
 TRISTAN (Trial of Inhaled Steroids and Long-Acting β_2 -Agonists), 183, 195-196, 195
 Tuberculosis, airflow limitation in, 53
 Tumor necrosis factor alpha (TNF- α), 35t, 46, 219
 in COPD exacerbations, 279, 280t
 inhibitors of, 219
 UK Medical Research Council, 126
 Ultra-long-acting β_2 agonist (indacaterol), 146t, 153-159
 Ultrasonic nebulizers, 216t
 Underdiagnosis of COPD, 18, 20
 Unidur, 208t
 Uniphyllin, 208t
 UPLIFT (Understanding Potential Long-term Impacts on Function With Tiotropium) study, 171, 172, 173, 290
 Urinary retention, 160
 US COPD Coalition, 306
 \dot{V}/\dot{Q} . See *Ventilation-perfusion*.
 Vaccinations, 90, 218, 289
 influenza, 90, 136, 218, 222t, 289, 289t
 pneumonia, 90, 218, 289, 289t
 Valsartan, 261
 Vancericil, 184t
 Vancericil DS, 184t
 Varenicline (Chantix), 103, 107-111
 adverse events, 111
 dosage, 111
 efficacy, 107-111, 108, 110, 112
 seven-day point prevalence of abstinence, 109-111, 110
 vs bupropion, 107-109, 108
 Vascular disease, 256t, 258-259. See also *Cardiovascular disorders*.
 Vascular surgery, 233
 Vasodilators, 220t, 257
 VC. See *Vital capacity*.
 VD/VT (dead space:tidal volume ratio), 72
 Ventilated alveolar volume (VA), 69
 Ventilation-perfusion (\dot{V}/\dot{Q})
 mismatching, 38t, 39, 43
 in exacerbations, 275, 280-281, 280t
 ratios, 39, 42, 280-281
 variability in, 42
 Ventilation support. See also *Oxygen therapy*.
 in end-stage disease, 300
 in exacerbations, 275, 285-286
 invasive, 286, 286t, 300
 indications for, 286, 286t
 noninvasive, 127-128, 285-286
 Ventodisk, 142t
 Ventolin, 140, 143t
 Ventolin Rotacap, 143t
 Vertebral fractures, 262
 Viagra (sildenafil), 257, 269
 Viral infections, 277-278, 278t
 Vital capacity (VC), 63, 66-68
 vertebral fractures and, 262
 Vitamin D supplements, 263t
 Volmax, 143t
 VT. See *Tidal volume*.
 Weakness, 57
 Weight categories (normal, underweight, overweight, obese), 124
 Weight gain
 COPD mortality and, 125
 smoking cessation and, 101, 102t
 Weight loss, 46, 57, 60, 122-124. See also *Muscle wasting and dysfunction*.
 BMI criteria for, 124
 consequences of, 122-123, 123
 COPD mortality and, 122-123, 123
 definition of, 124
 as indication for nutritional supplementation, 124-125
 mechanisms of, 268, 268
 pathogenesis of, 123-124
 with roflumilast, 212, 214, 292
 Wheezing, 18, 56, 277
 Women
 aggressive/progressive course of COPD in, 24
 estrogen and, 24-25
 mortality rates from COPD, 19-20, 19
 nomogram for predicting lung age, 85, 89
 prevalence of COPD in, 20, 24-25
 smoking in, 20
 Work of breathing
 in COPD (increased), 39, 60
 in exacerbations, 280t, 281

World Health Organization (WHO), 235, 306. See also *GOLD (Global Initiative for Chronic Obstructive Lung Disease)*.
Framework Convention on Tobacco Control, 23
global prevalence of COPD, 18
tobacco-free initiative (treaty), 23

X-rays. See *Radiography*.

Xopenex (levalbuterol), 140, 144t